GLP-1 medications, or glucagon-like peptide-1 receptor agonists, are a class of drugs primarily used to manage type 2 diabetes and, more recently, obesity
The intestinal-hepatic crosstalk constitutes a pivotal component of MASLD development, linking intestinal dysbiosis to hepatic inflammation and fibrosis [1]
Ce phnomne est l'un des mieux documents dans la littrature sur le vieillissement oxydatif
These compounds work primarily on hepatic lipid metabolism and mitochondrial function
New data on Hengrui Pharma and Kailera Therapeutics investigational oral GLP-1 have validated the late-stage weight loss asset and paved the road for a regulatory submission in China, but analysts pointed to high rates of nausea and vomiting that could challenge the ongoing U.S
The Double Hit: Weight Loss + Direct Skin Aging The result is a double-aging effect part of it from losing structural fat (which happens with any major weight loss), but part of it from biological changes to the skin itself that appear to be caused by the medication
